Literature DB >> 9740226

Effects of ultraviolet B radiation on human Langerhans cells: functional alteration of CD86 upregulation and induction of apoptotic cell death.

F M Rattis1, M Concha, C Dalbiez-Gauthier, P Courtellemont, D Schmitt, J Péguet-Navarro.   

Abstract

We have recently reported that in vitro low dose of ultraviolet B radiation (UVB, 100-200 J per m2) directly impaired the antigen-presenting function of human Langerhans cells. In this study, we analyzed the effect of UVB irradiation on the Langerhans cells expression of several accessory molecules, namely CD54, CD80, and CD86. Langerhans cells phenotype was determined either immediately after UVB exposure (100 J per m2) or after a 2 d culture. No modification in cell surface antigen levels was observed immediately after irradiation. Prior UVB exposure did not modify the levels of CD80 at the Langerhans cells surface after a 2 d culture. In contrast, CD54 and, above all, CD86 expression were significantly decreased. Addition of exogenous anti-CD28 monoclonal antibodies partly restored the allostimulatory property of irradiated Langerhans cells in mixed epidermal cell-lymphocyte reaction, demonstrating that impairment of CD86 upregulation contributes to the UVB-induced immunosuppressive effect. Furthermore, we found that UVB irradiation at 200 J per m2 significantly reduced the number of viable Langerhans cells after 2 d of culture. UVB-induced cytotoxicity was due to apoptotic cell death, as demonstrated by typical morphologic alterations and by DNA fragmentation yielding a classical ladder pattern on gel electrophoresis. Interestingly, interaction of Langerhans cells with CD40-ligand transfected L cells improved the viability of irradiated Langerhans cells, counteracted the inhibition of CD86 expression, and efficiently reduced the number of apoptotic cells after a 2 d culture. Collectively, these results demonstrate that in vitro UVB exposure affects Langerhans cells via at least two distinct pathways: (i) decreased CD86 costimulatory molecule upregulation; and (ii) induction of Langerhans cells apoptosis, a phenomenon partly prevented by CD40 triggering.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740226     DOI: 10.1046/j.1523-1747.1998.00320.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  Carcinogen-modified dendritic cells induce immunosuppression by incomplete T-cell activation resulting from impaired antigen uptake and reduced CD86 expression.

Authors:  G M Woods; K V Doherty; R C Malley; M J Rist; H K Muller
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Accumulation of CD1a-positive Langerhans cells and mast cells in actinic cheilitis.

Authors:  Caliandra Pinto Araújo; Clarissa Araújo Silva Gurgel; Eduardo Antônio Gonçalves Ramos; Valéria Souza Freitas; Aryon de Almeida Barbosa; Luciana Maria Pedreira Ramalho; Jean Nunes dos Santos
Journal:  J Mol Histol       Date:  2010-10-02       Impact factor: 2.611

Review 3.  Metal nanomaterials: Immune effects and implications of physicochemical properties on sensitization, elicitation, and exacerbation of allergic disease.

Authors:  Katherine A Roach; Aleksandr B Stefaniak; Jenny R Roberts
Journal:  J Immunotoxicol       Date:  2019-12       Impact factor: 3.000

4.  Endonasal phototherapy significantly alleviates symptoms of allergic rhinitis, but has a limited impact on the nasal mucosal immune cells.

Authors:  Detlef Brehmer; Michael P Schön
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-09-03       Impact factor: 2.503

5.  Tumor-promoting role of TGFβ1 signaling in ultraviolet B-induced skin carcinogenesis is associated with cutaneous inflammation and lymph node migration of dermal dendritic cells.

Authors:  Anand Ravindran; Javed Mohammed; Andrew J Gunderson; Xiao Cui; Adam B Glick
Journal:  Carcinogenesis       Date:  2013-12-20       Impact factor: 4.944

Review 6.  Immunopathogenic mechanisms in psoriasis.

Authors:  J E Gudjonsson; A Johnston; H Sigmundsdottir; H Valdimarsson
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.